Oral strain I Oral health
Characteristics
DAILY DOSAGE IN CLINICAL STUDY
0.5B CFU/tablet
FUNCTIONALITY
Oral health (reductions of tonsillitis, laryngitis, and dental caries)
Scientific support
Human clinical trials
Di Pierro, F, G. Donato, F. Fomia, T. Adami, D. Careddu, C. Cassandro, and R. Albera. “Preliminary pediatric clinical evaluation of the oral probiotic Streptococcus salivarius K12 in preventing recurrent pharyngitis and/or tonsillitis caused by Streptococcus pyogenes and recurrent acute otitis media.” International journal of general medicine 5 (2012): 991.
Burton, J. P., C. N. Chilcott, C. J. Moore, G. Speiser, and J. R. Tagg.. “A preliminary study of the effect of probiotic Streptococcus salivarius K12 on oral malodour parameters.” Journal of applied microbiology 100.4 (2006): 754-764.
